Life Science Nation Newsletter  |  July 7, 2016  |  Issue 169

  The LSN Story   |   Investor Platform   |   Company Platform   |   RESI Conference   |   Fundraising Consulting
Life Science Investor Mandates (June 30 - July 6)
Seeks Devices in Gastroenterology and Urology
Seeks Early Stage Therapeutics, Medtech, and Personalized Medicine in Chronic Diseases
Invests In Data & Machine Learning, Connected Technologies in Healthcare
Seeks Therapeutics In Immunology, Neuroscience and Oncology
In This Issue
Nature BioEntrepreneur Features LSN: Aligning Needs
LSN Videos
RESI Landing on MaRS

RESI @ TMCx Investors Panel

By Caitlin Kramer, Research Analyst, LSN

Advances in computer science and engineering in recent decades mirror and enable advances in the life sciences. The trends of miniaturization, massive parallelization, and faster processing are now applicable to cell handling, and investors are therefore taking a keen interest in this rapidly developing field.

Current instruments aim to separate and enrich desired cells from complex matrices using smaller sample sizes, all while shrinking device size to handheld or benchtop scale. Many of these new technologies make use of microfluidics and/or microelectromechanical systems (MEMS) which employ microscale electric, acoustic, or magnetic fields to separate cells on the basis of character...

By Lucy Parkinson, Director of Research, LSN

18 months ago, Next Phase took a look into assets under development in the neurology space. Revisiting that sector now, we see some fields moving ahead in spite of the great challenges involved in the development of neurology assets.

Drawing on a sample from the LSN Company Platform of assets under development worldwide, we can take a look at the top areas in both diseases of the nervous system and in mental and behavioral disorders. In diseases of the nervous system, this sample includes 647 assets, of which 464 relate to a specific clinical area...

By Nono Hu, Director of Marketing, LSN

Last week we discussed how to determine where your company fits within your marketplace. Once you have completed that process, the next step in a fundraising campaign is to develop your marketing materials. In this week's edition of the summer reading series, we describe the importance of and what constitutes a strong set of marketing materials in the life science fundraising world. While your team and your technology are what will ultimately secure an allocation, having marketing collateral that clearly and concisely communicates your message will help you tremendously in getting in the door with investors.

Chapter 6 of The Life Science Executive's Fundraising Manifesto discusses in depth the different pieces of marketing collateral you should be putting into the marketplace and how to develop everything from your logo to your pitch deck.


Life Science Nation | 9B Hamilton Place | Boston | MA | 02108